Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

Inclusion Criteria: * Adult patients, ages 18-100, with chemotherapy-induced peripheral neuropathy as a primary source of pain * The patient is already scheduled to be treated with TDD using ziconotide (no reported allergies to ziconotide or drug-drug interactions expected) * Patient will have, or is scheduled to have, Medtronic Synchromed Intrathecal Pump implanted by Dr. Beuer (outside of the research) * Patients already taking nonopioid analgesics will be allowed to continue their prescribed medication regimen. * Patients currently taking opioid analgesics must undergo a washout period of 2 weeks (prior to device implant) before participating in this study. Those unable to adhere to this washout period will be excluded Exclusion Criteria: * Patients with other forms of neuropathy (diabetic, idiopathic) will be excluded * Patients with a spinal cord stimulator will be excluded * Patients with contraindications to intrathecal ziconotide will be excluded * Patients who cannot sign the consent, participate in research activities, or those who require a legally authorized representative (LAR) will be excluded * Patients who are pregnant and/or nursing or planning to become pregnant are excluded * Also excluded are those inaccessible for follow-up, participation is excluded by local law, or a patient is currently enrolled or plans to enroll in a concurrent drug/device study